Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
May 29th 2008
Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR™ with Dr. Stephan Mielke and...
read more 
(NL version)
(NL version)
Kiadis Pharma receives Orphan Drug Designation for Rhitol™ from the FDA
Apr 15th 2008
Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol™ Orphan Drug...
read more (NL version)
(NL version)
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ presented by NIH investigators - Mar 25th 2008 (NL)
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™ - Feb 22nd 2008 (NL)
- Kiadis Pharma announces successful completion of Rhitol™ Phase II clinical study - Jan 31st 2008 (NL)
- Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc - Dec 19th 2007 (NL)
- ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments - Dec 14th 2007 (NL)
1098 VA Amsterdam
The Netherlands
t +31 (0)20 888 48 15
f +31 (0)20 888 48 63
Zernikepark 6-8
9747 AN Groningen
The Netherlands
t +31 (0) 50 547 42 70
f +31 (0) 50 547 42 71
2525 ave. Marie-Curie
Saint-Laurent (Quebec)
Canada H4S 2E1
t +1 (514) 336-4886
f +1 (514) 336-7329